Dysadherin inhibition reduces both cancer stemness and immune evasion, highlighting its potential as a therapeutic target and supporting combination strategies with PD-1/PD-L1 inhibitors in immune-refractory HCC. Here, PDCD1 is linked to hepatocellular carcinoma.